Loading...
XSHE
300497
Market cap678mUSD
Jul 09, Last price  
9.05CNY
1D
-0.55%
1Q
17.38%
Jan 2017
-40.40%
IPO
114.61%
Name

Jiangxi Fushine Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300497 chart
P/E
—
P/S
3.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.63%
Rev. gr., 5y
6.71%
Revenues
1.61b
-2.28%
291,367,461360,320,580442,842,086510,727,122579,743,065763,686,934958,150,4761,163,433,5901,354,046,8111,492,952,9901,429,542,8741,647,263,4261,609,669,988
Net income
-201m
35,847,26840,079,43245,072,68753,441,24193,601,767173,909,446177,550,392194,724,797305,835,258319,300,20048,830,6620-200,800,049
CFO
-65m
063,195,80557,219,00131,389,54774,008,650188,534,194210,723,307175,913,935337,910,973382,350,65172,321,5560-64,762,951
Dividend
Jul 08, 20210.2 CNY/sh

Profile

Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers penicillin, carbapenem, and other products. It also provides contract research, development, and manufacturing services. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is based in Jingdezhen, China.
URL
http://www.fushine.cn/
IPO date
Dec 22, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,609,670
-2.28%
1,647,263
15.23%
Cost of revenue
1,645,339
1,504,576
Unusual Expense (Income)
NOPBT
(35,669)
142,687
NOPBT Margin
8.66%
Operating Taxes
(9,915)
21,467
Tax Rate
15.04%
NOPAT
(25,755)
121,220
Net income
(200,800)
 
Dividends
(55,790)
Dividend yield
1.10%
Proceeds from repurchase of equity
(20,913)
BB yield
0.41%
Debt
Debt current
628,606
374,693
Long-term debt
998,264
1,043,044
Deferred revenue
62,385
62,027
Other long-term liabilities
1
1
Net debt
626,227
168,291
Cash flow
Cash from operating activities
(64,763)
CAPEX
(242,225)
Cash from investing activities
(354,502)
Cash from financing activities
149,765
282,987
FCF
(334,690)
(363,056)
Balance
Cash
731,556
1,027,769
Long term investments
269,086
221,677
Excess cash
920,159
1,167,083
Stockholders' equity
1,072,563
1,465,026
Invested Capital
3,239,836
2,985,034
ROIC
4.35%
ROCE
3.43%
EV
Common stock shares outstanding
542,703
538,649
Price
9.36
-29.09%
13.20
-19.17%
Market cap
5,079,699
-28.56%
7,110,166
-19.99%
EV
5,691,867
7,286,854
EBITDA
123,789
266,525
EV/EBITDA
45.98
27.34
Interest
42,031
41,098
Interest/NOPBT
28.80%